

# Sarah E Pinder

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9580432/sarah-e-pinder-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

327  
papers

20,662  
citations

71  
h-index

134  
g-index

349  
ext. papers

23,884  
ext. citations

5.9  
avg, IF

6.16  
L-index

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 327 | Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study.. <i>Breast</i> , <b>2022</b> , 61, 145-155   | 3.6  | 0         |
| 326 | Macrophages orchestrate the expansion of a proangiogenic perivascular niche during cancer progression. <i>Science Advances</i> , <b>2021</b> , 7, eabg9518  | 14.3 | 2         |
| 325 | Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 24   | 7.8  | 4         |
| 324 | Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio $\geq 0$ , HER2 copy number). <i>British Journal of Cancer</i> , <b>2021</b> , 124, 1836-1842 | 8.7  | 2         |
| 323 | Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma : Results from the UK/ANZ DCIS Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2861-2867  | 12.9 | 4         |
| 322 | Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer. <i>Cancer Research</i> , <b>2021</b> , 81, 4290-4304   | 10.1 | 10        |
| 321 | Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial. <i>Annals of Oncology</i> , <b>2021</b> , 32, 58-65  | 10.3 | 3         |
| 320 | Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 1009-1017  | 8.7  | 12        |
| 319 | Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. <i>Histopathology</i> , <b>2021</b> , 78, 759-771  | 7.3  | 3         |
| 318 | Variability in grading of ductal carcinoma in situ among an international group of pathologists. <i>Journal of Pathology: Clinical Research</i> , <b>2021</b> , 7, 233-242  | 5.3  | 3         |
| 317 | Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. <i>Modern Pathology</i> , <b>2021</b> , 34, 1271-1281  | 9.8  | 12        |
| 316 | Reply to "Comment on: Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project". <i>British Journal of Cancer</i> , <b>2021</b> , 124, 1463-1464   | 8.7  | 1         |
| 315 | Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 86  | 7.8  | 1         |
| 314 | Low-risk DCIS. What is it? Observe or excise?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2021</b> , 1  | 5.1  | 1         |
| 313 | Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma : Results from the UK/ANZ DCIS Randomized Trial. <i>Clinical Cancer Research</i> , <b>2021</b> ,   | 12.9 | 3         |
| 312 | Invasive breast cancer over four decades reveals persisting poor metastatic outcomes in treatment resistant subgroup - the "ATRESS" phenomenon. <i>Breast</i> , <b>2020</b> , 50, 39-48   | 3.6  | 6         |
| 311 | Abstract P4-07-04: Genomic analysis of paired DCIS and subsequent recurrence to assess clonal relatedness in screen detected DCIS <b>2020</b> ,   |      | 2         |

|     |  |      |     |
|-----|--|------|-----|
| 310 | Low-grade adenosquamous carcinoma arising in association with a nipple adenoma. <i>Histopathology</i> , <b>2020</b> , 76, 784-787  | 7.3  | 4   |
| 309 | Real-time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study. <i>Journal of Pathology</i> , <b>2020</b> , 250, 262-274  | 9.4  | 5   |
| 308 | Cancer-associated hypersialylated MUC1 drives the differentiation of human monocytes into macrophages with a pathogenic phenotype. <i>Communications Biology</i> , <b>2020</b> , 3, 644  | 6.7  | 13  |
| 307 | Screening detects a myriad of breast disease - refining practice will increase effectiveness and reduce harm. <i>British Journal of Radiology</i> , <b>2020</b> , 93, 20200135   | 3.4  |     |
| 306 | Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): an overview of presentation and pathogenesis and guidelines for pathological diagnosis and management. <i>Histopathology</i> , <b>2019</b> , 75, 787-796                  | 7.3  | 26  |
| 305 | Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 58                                | 8.3  | 7   |
| 304 | Frequency of Pathogenic Germline Variants in , and in Sporadic Lobular Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 1162-1168   | 4    | 12  |
| 303 | The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. <i>Journal of Clinical Epidemiology</i> , <b>2019</b> , 106, 108-120   | 5.7  | 32  |
| 302 | An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. <i>Journal of Clinical Epidemiology</i> , <b>2018</b> , 99, 75-83 | 5.7  | 18  |
| 301 | Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 429-435   | 3.6  | 41  |
| 300 | In situ lobular proliferations of the breast. <i>Diagnostic Histopathology</i> , <b>2018</b> , 24, 58-63   | 0.7  | 2   |
| 299 | The importance of histological assessment after the adjuvant therapy and the need for standardisation. <i>Clinical Radiology</i> , <b>2018</b> , 73, 693-699   | 2.9  | 4   |
| 298 | Ductal Carcinoma in Situ <b>2018</b> , 115-126   |      |     |
| 297 | Pathology of High-Risk Breast Lesions <b>2018</b> , 103-114  |      |     |
| 296 | Pleomorphic LCIS what do we know? A UK multicenter audit of pleomorphic lobular carcinoma in situ. <i>Breast</i> , <b>2018</b> , 38, 120-124   | 3.6  | 11  |
| 295 | Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers. <i>Journal of Pathology: Clinical Research</i> , <b>2018</b> , 4, 39-54     | 5.3  | 14  |
| 294 | Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. <i>Nature Medicine</i> , <b>2018</b> , 24, 628-637   | 50.5 | 410 |
| 293 | Diagnostic concordance of reporting lymphovascular invasion in breast cancer. <i>Journal of Clinical Pathology</i> , <b>2018</b> , 71, 802-805   | 3.9  | 8   |

|     |   |      |     |
|-----|---|------|-----|
| 292 | High-intensity focused ultrasound in the treatment of breast fibroadenomata (HIFU-F trial). <i>International Journal of Hyperthermia</i> , <b>2018</b> , 34, 1002-1009  | 3.7  | 6   |
| 291 | NHS Breast Screening multidisciplinary working group guidelines for the diagnosis and management of breast lesions of uncertain malignant potential on core biopsy (B3 lesions). <i>Clinical Radiology</i> , <b>2018</b> , 73, 682-692  | 2.9  | 53  |
| 290 | Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5098-5111  | 12.9 | 41  |
| 289 | Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients. <i>Journal of Pathology: Clinical Research</i> , <b>2018</b> , 4, 262-273 | 5.3  | 24  |
| 288 | Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project. <i>European Journal of Cancer</i> , <b>2018</b> , 101, 210-219   | 7.5  | 34  |
| 287 | Bilateral Inflammatory Pseudotumour of the Breast: A Case Report and Review of the Literature. <i>The Journal of Breast Health</i> , <b>2018</b> , 14, 229-233  | 1.5  | 1   |
| 286 | Invasion in breast lesions: the role of the epithelial-stroma barrier. <i>Histopathology</i> , <b>2018</b> , 72, 1075-1083  | 7.3  | 13  |
| 285 | Molecular patterns of cancer colonisation in lymph nodes of breast cancer patients. <i>Breast Cancer Research</i> , <b>2018</b> , 20, 143   | 8.3  | 10  |
| 284 | An audit of residual cancer burden reproducibility in a UK context. <i>Histopathology</i> , <b>2017</b> , 70, 217-222   | 7.3  | 12  |
| 283 | Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival. <i>Scientific Reports</i> , <b>2017</b> , 7, 40177   | 4.9  | 8   |
| 282 | ROR $\beta$ Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers. <i>Cancer Research</i> , <b>2017</b> , 77, 1083-1096   | 10.1 | 71  |
| 281 | Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 859-863   | 8.7  | 7   |
| 280 | Automated Classification of Breast Cancer Stroma Maturity From Histological Images. <i>IEEE Transactions on Biomedical Engineering</i> , <b>2017</b> , 64, 2344-2352  | 5    | 36  |
| 279 | Review of the national external quality assessment (EQA) scheme for breast pathology in the UK. <i>Journal of Clinical Pathology</i> , <b>2017</b> , 70, 51-57  | 3.9  | 28  |
| 278 | Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. <i>Nature</i> , <b>2017</b> , 543, 714-718   | 50.4 | 157 |
| 277 | Intraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery Using F-FDG Cerenkov Luminescence Imaging: A First-in-Human Feasibility Study. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 891-898   | 8.9  | 69  |
| 276 | The impact of human epidermal growth factor receptor 2 neoadjuvant monoclonal antibody (trastuzumab) therapy in ductal carcinoma in situ of the breast. <i>Histopathology</i> , <b>2017</b> , 70, 1009-1011   | 7.3  | 2   |
| 275 | Microstructural models for diffusion MRI in breast cancer and surrounding stroma: an ex vivo study. <i>NMR in Biomedicine</i> , <b>2017</b> , 30, e3679   | 4.4  | 20  |

|     |   |      |     |
|-----|---|------|-----|
| 274 | The B3 conundrum-the radiologists perspective. <i>British Journal of Radiology</i> , <b>2017</b> , 90, 20160595   | 3.4  | 10  |
| 273 | Modern therapies and iatrogenic changes in breast pathology. <i>Histopathology</i> , <b>2017</b> , 70, 40-55  | 7.3  | 6   |
| 272 | Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study. <i>Breast Cancer Research</i> , <b>2017</b> , 19, 113               | 8.3  | 3   |
| 271 | Reply to R.F. Sweis et al. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 261-262  | 2.2  | 1   |
| 270 | Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice. <i>Clinical Oncology</i> , <b>2017</b> , 29, 642-652   | 2.8  | 69  |
| 269 | PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression. <i>Breast Cancer Research</i> , <b>2017</b> , 19, 7   | 8.3  | 13  |
| 268 | Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?. <i>Histopathology</i> , <b>2017</b> , 70, 681-692  | 7.3  | 11  |
| 267 | Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme. <i>Histopathology</i> , <b>2017</b> , 70, 632-642 | 7.3  | 14  |
| 266 | Micro- and macro-metastasis in the axillary lymph node: A review. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , <b>2017</b> , 15, 76-82  | 2.5  | 13  |
| 265 | Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 566-567   | 3.1  | 7   |
| 264 | Use of a handheld terahertz pulsed imaging device to differentiate benign and malignant breast tissue. <i>Biomedical Optics Express</i> , <b>2017</b> , 8, 2932-2945  | 3.5  | 48  |
| 263 | Proliferative Breast Lesions <b>2017</b> , 33-41  |      |     |
| 262 | Problematic Core Biopsies <b>2017</b> , 43-60   |      |     |
| 261 | The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. <i>Nature Communications</i> , <b>2016</b> , 7, 11479  | 17.4 | 779 |
| 260 | Magnetic Technique for Sentinel Lymph Node Biopsy in Melanoma: The MELAMAG Trial. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 2070-8   | 3.1  | 12  |
| 259 | A review of ablative techniques in the treatment of breast fibroadenomata. <i>Journal of Therapeutic Ultrasound</i> , <b>2016</b> , 4, 1  |      | 7   |
| 258 | Classification of breast cancer stroma as a tool for prognosis <b>2016</b> ,  |      | 1   |
| 257 | Family history of breast cancer and its association with disease severity and mortality. <i>Cancer Medicine</i> , <b>2016</b> , 5, 942-9  | 4.8  | 20  |

|     |  |      |     |
|-----|--|------|-----|
| 256 | Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1987-94                                    | 2.2  | 64  |
| 255 | Immunohistochemistry for Triple-Negative Breast Cancer. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1406, 39-51  | 1.4  | 2   |
| 254 | Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 88-95   | 8.7  | 9   |
| 253 | Treatment and outcomes from a large, prospective, national longitudinal cohort study of screen detected ductal carcinoma in situ (DCIS).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1570-1570  | 2.2  | 0   |
| 252 | HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. <i>Oncotarget</i> , <b>2016</b> , 7, 51012-51026   | 3.3  | 22  |
| 251 | OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. <i>Health Technology Assessment</i> , <b>2016</b> , 20, xxiii-xxix, 1-201   | 4.4  | 42  |
| 250 | OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS623-TPS623 | 2.2  | 2   |
| 249 | Accuracy of classification of invasive lobular carcinoma on needle core biopsy of the breast. <i>Journal of Clinical Pathology</i> , <b>2016</b> , 69, 1122-1123   | 3.9  | 2   |
| 248 | Two E-selectin ligands, BST-2 and LGALS3BP, predict metastasis and poor survival of ER-negative breast cancer. <i>International Journal of Oncology</i> , <b>2016</b> , 49, 265-75   | 4.4  | 23  |
| 247 | Viewpoint: Availability of oestrogen receptor and HER2 status for the breast multidisciplinary meeting discussion; time to get it right. <i>European Journal of Surgical Oncology</i> , <b>2016</b> , 42, 994-8  | 3.6  | 5   |
| 246 | The radiological features, diagnosis and management of screen-detected lobular neoplasia of the breast: Findings from the Sloane Project. <i>Breast</i> , <b>2016</b> , 27, 109-15   | 3.6  | 18  |
| 245 | Genetic predisposition to ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 22   | 8.3  | 31  |
| 244 | Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,   | 9.7  | 114 |
| 243 | High intensity focused ultrasound in the treatment of breast fibroadenomata: results of the HIFU-F trial. <i>International Journal of Hyperthermia</i> , <b>2016</b> , 32, 881-888   | 3.7  | 21  |
| 242 | A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. <i>Molecular Oncology</i> , <b>2015</b> , 9, 115-27   | 7.9  | 35  |
| 241 | Nottingham Clinico-Pathological Response Index (NPRI) after neoadjuvant chemotherapy (Neo-ACT) accurately predicts clinical outcome in locally advanced breast cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1052-62   | 12.9 | 14  |
| 240 | Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches. <i>Histopathology</i> , <b>2015</b> , 67, 279-93   | 7.3  | 21  |
| 239 | Updated UK Recommendations for HER2 assessment in breast cancer. <i>Journal of Clinical Pathology</i> , <b>2015</b> , 68, 93-9   | 3.9  | 155 |

|     |   |      |     |
|-----|---|------|-----|
| 238 | Optimising magnetic sentinel lymph node biopsy in an in vivo porcine model. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2015</b> , 11, 993-1002   | 6    | 4   |
| 237 | Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1280-91   | 10.3 | 127 |
| 236 | Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. <i>Cancer Discovery</i> , <b>2015</b> , 5, 488-505   | 24.4 | 76  |
| 235 | Addressing overtreatment of screen detected DCIS; the LORIS trial. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 2296-303   | 7.5  | 197 |
| 234 | Selection and evolution in the genomic landscape of copy number alterations in ductal carcinoma in situ (DCIS) and its progression to invasive carcinoma of ductal/no special type: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 153, 101-21                              | 4.4  | 15  |
| 233 | Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value. <i>BMC Cancer</i> , <b>2015</b> , 15, 546   | 4.8  | 21  |
| 232 | Models of breast morphogenesis based on localization of stem cells in the developing mammary lobule. <i>Stem Cell Reports</i> , <b>2015</b> , 4, 699-711  | 8    | 24  |
| 231 | PAK4 promotes kinase-independent stabilization of RhoU to modulate cell adhesion. <i>Journal of Cell Biology</i> , <b>2015</b> , 211, 863-79  | 7.3  | 42  |
| 230 | Systematic review of high-intensity focused ultrasound ablation in the treatment of breast cancer. <i>British Journal of Surgery</i> , <b>2015</b> , 102, 873-82; discussion 882  | 5.3  | 47  |
| 229 | Comparison of three magnetic nanoparticle tracers for sentinel lymph node biopsy in an in vivo porcine model. <i>International Journal of Nanomedicine</i> , <b>2015</b> , 10, 1235-43  | 7.3  | 23  |
| 228 | Minimum slice spacing required to reconstruct 3D shape for serial sections of breast tissue for comparison with medical imaging <b>2015</b> ,   |      | 2   |
| 227 | Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. <i>Journal of Pathology: Clinical Research</i> , <b>2015</b> , 1, 18-32   | 5.3  | 18  |
| 226 | Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. <i>Annals of Oncology</i> , <b>2015</b> , 26, 75-80   | 10.3 | 72  |
| 225 | Concordance of intrinsic subtyping and risk of recurrence (ROR) scores between matched primary and metastatic tissue from Triple Negative Breast Cancer Trial (TNT).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1019-1019   | 2.2  | 1   |
| 224 | Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 144, 331-41 | 4.4  | 2   |
| 223 | Sentinel node biopsy using a magnetic tracer versus standard technique: the SentiMAG Multicentre Trial. <i>Annals of Surgical Oncology</i> , <b>2014</b> , 21, 1237-45  | 3.1  | 134 |
| 222 | Addendum to BASOII Trial report. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2517-8   | 7.5  | 1   |
| 221 | Growth hormone is secreted by normal breast epithelium upon progesterone stimulation and increases proliferation of stem/progenitor cells. <i>Stem Cell Reports</i> , <b>2014</b> , 2, 780-93   | 8    | 35  |



|     |   |     |     |
|-----|---|-----|-----|
| 220 | Adverse surgical outcomes in screen-detected ductal carcinoma in situ of the breast. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 1880-90  | 7.5 | 13  |
| 219 | HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice. <i>Journal of Clinical Pathology</i> , <b>2014</b> , 67, 161-7   | 3.9 | 13  |
| 218 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast. <i>PLoS Genetics</i> , <b>2014</b> , 10, e1004285   | 6   | 38  |
| 217 | The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility. <i>Science Signaling</i> , <b>2014</b> , 7, ra78  | 8.8 | 28  |
| 216 | Breast cancer with neoductogenesis: histopathological criteria and its correlation with mammographic and tumour features. <i>International Journal of Breast Cancer</i> , <b>2014</b> , 2014, 581706  | 2.3 | 11  |
| 215 | Aldehyde dehydrogenase and estrogen receptor define a hierarchy of cellular differentiation in the normal human mammary epithelium. <i>Breast Cancer Research</i> , <b>2014</b> , 16, R52   | 8.3 | 40  |
| 214 | Age at diagnosis and distant metastasis in breast cancer--a surprising inverse relationship. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 1697-1705  | 7.5 | 49  |
| 213 | Germline CDH1 mutations in bilateral lobular carcinoma in situ. <i>British Journal of Cancer</i> , <b>2014</b> , 110, 105387  |     | 54  |
| 212 | Pathological Nipple Discharge. <i>Open Access Journal of Science and Technology</i> , <b>2014</b> , 2,  |     | 3   |
| 211 | Modelling Vascularity in Breast Cancer and Surrounding Stroma Using Diffusion MRI and Intravoxel Incoherent Motion. <i>Lecture Notes in Computer Science</i> , <b>2014</b> , 380-386  | 0.9 |     |
| 210 | Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium <b>2014</b> , n/a-n/a  |     | 1   |
| 209 | Patterns of metastatic spread in early breast cancer. <i>Breast</i> , <b>2013</b> , 22, 449-54  | 3.6 | 24  |
| 208 | Challenges in the management of pleomorphic lobular carcinoma in situ of the breast. <i>Breast</i> , <b>2013</b> , 22, 194-196  | 3.6 | 26  |
| 207 | Pathological controversies in breast cancer: classification of ductal carcinoma in situ, sentinel lymph nodes and low volume metastatic disease and reporting of neoadjuvant chemotherapy specimens. <i>Clinical Oncology</i> , <b>2013</b> , 25, 80-92 | 2.8 | 9   |
| 206 | Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 2294-302                                  | 7.5 | 140 |
| 205 | Deposition of superparamagnetic iron-oxide nanoparticles in axillary sentinel lymph nodes following subcutaneous injection. <i>Histopathology</i> , <b>2013</b> , 62, 481-6   | 7.3 | 49  |
| 204 | Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. <i>Modern Pathology</i> , <b>2013</b> , 26, 955-66   | 9.8 | 63  |
| 203 | Synchronous ductal carcinoma in situ of the breast and within epithelial inclusions in an ipsilateral sentinel lymph node. <i>Human Pathology</i> , <b>2013</b> , 44, 142-4   | 3.7 | 5   |



|     |  |      |      |
|-----|--|------|------|
| 202 | Magnetic sentinel lymph node biopsy and localization properties of a magnetic tracer in an in vivo porcine model. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 141, 33-42   | 4.4  | 13   |
| 201 | The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. <i>Journal of Clinical Pathology</i> , <b>2013</b> , 66, 169-77   | 3.9  | 34   |
| 200 | Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. <i>BMC Genomics</i> , <b>2013</b> , 14, 643  | 4.5  | 68   |
| 199 | Histological risk factors, prognostic indicators and staging <b>2013</b> , 236-249   |      |      |
| 198 | Current issues in diagnostic breast pathology. <i>Journal of Clinical Pathology</i> , <b>2012</b> , 65, 771-85   | 3.9  | 24   |
| 197 | Invasive Lobular Carcinoma of the Breast. <i>Surgical Pathology Clinics</i> , <b>2012</b> , 5, 545-66  | 3.9  | 1    |
| 196 | Ductal carcinoma in situ: current morphological and molecular subtypes. <i>Diagnostic Histopathology</i> , <b>2012</b> , 18, 112-118   | 0.7  | 2    |
| 195 | Classification of terahertz-pulsed imaging data from excised breast tissue. <i>Journal of Biomedical Optics</i> , <b>2012</b> , 17, 016005   | 3.5  | 68   |
| 194 | The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. <i>Nature</i> , <b>2012</b> , 486, 346-52   | 50.4 | 3479 |
| 193 | Comparative immunohistochemical analysis of ochratoxin A tumourigenesis in rats and urinary tract carcinoma in humans; mechanistic significance of p-S6 ribosomal protein expression. <i>Toxins</i> , <b>2012</b> , 4, 643-62  | 4.9  | 10   |
| 192 | A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2296-2300                  | 10.3 | 39   |
| 191 | HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. <i>Journal of Clinical Pathology</i> , <b>2011</b> , 64, 649-53  | 3.9  | 55   |
| 190 | Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 21-9  | 21.7 | 371  |
| 189 | Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. <i>Cancer Research</i> , <b>2011</b> , 71, 7683-93   | 10.1 | 126  |
| 188 | Breast: Ductal Carcinoma In Situ (DCIS) <b>2011</b> , 421-436  |      |      |
| 187 | Comparison of margin assessment by radial and shave sections in wide local excision specimens for invasive carcinoma of the breast. <i>Histopathology</i> , <b>2010</b> , 56, 573-80   | 7.3  | 10   |
| 186 | Radiological and pathological size estimations of pure ductal carcinoma in situ of the breast, specimen handling and the influence on the success of breast conservation surgery: a review of 2564 cases from the Sloane Project. <i>British Journal of Cancer</i> , <b>2010</b> , 102, 285-93 | 8.7  | 43   |
| 185 | A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. <i>British Journal of Cancer</i> , <b>2010</b> , 103, 94-100  | 8.7  | 95   |

|     |   |     |     |
|-----|---|-----|-----|
| 184 | Over-expression of ST3Gal-I promotes mammary tumorigenesis. <i>Glycobiology</i> , <b>2010</b> , 20, 1241-50   | 5.8 | 96  |
| 183 | Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast?. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3552-4   | 2.2 | 38  |
| 182 | Oncological outcomes in rats given nephrocarcinogenic exposure to dietary ochratoxin a, followed by the tumour promoter sodium barbital for life: a pilot study. <i>Toxins</i> , <b>2010</b> , 2, 552-71  | 4.9 | 8   |
| 181 | Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation. <i>Modern Pathology</i> , <b>2010</b> , 23 Suppl 2, S8-13   | 9.8 | 70  |
| 180 | Lesion size is a major determinant of the mammographic features of ductal carcinoma in situ: findings from the Sloane project. <i>Clinical Radiology</i> , <b>2010</b> , 65, 181-4  | 2.9 | 21  |
| 179 | An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC testing guidelines. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2010</b> , 18, 189-93 | 1.9 | 5   |
| 178 | Experts and performance in histopathology—a study in breast pathology. <i>Pathology Research and Practice</i> , <b>2010</b> , 206, 749-52   | 3.4 | 1   |
| 177 | Terahertz pulsed spectroscopy of freshly excised human breast cancer. <i>Optics Express</i> , <b>2009</b> , 17, 12444-54  | 5.3 | 414 |
| 176 | Lymphatic drainage pathways of the breast and the upper limb. <i>Nuclear Medicine Communications</i> , <b>2009</b> , 30, 427-30   | 1.6 | 28  |
| 175 | Pre-operative diagnosis of breast cancer in screening: problems and pitfalls. <i>Pathology</i> , <b>2009</b> , 41, 3-17   | 1.6 | 11  |
| 174 | Implications of inconsistent measurement of ER status in non-invasive breast cancer: a study of 1,684 cases from the Sloane Project. <i>Breast Journal</i> , <b>2008</b> , 14, 33-8   | 1.2 | 17  |
| 173 | Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. <i>Breast</i> , <b>2008</b> , 17, 323-34   | 3.6 | 294 |
| 172 | An intra-operative THz probe for use during the surgical removal of breast tumors <b>2008</b> ,   |     | 14  |
| 171 | HER2 testing in the UK: further update to recommendations. <i>Journal of Clinical Pathology</i> , <b>2008</b> , 61, 818-24  | 3.4 | 107 |
| 170 | Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. <i>International Journal of Cancer</i> , <b>2008</b> , 122, 298-304  | 7.5 | 168 |
| 169 | A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. <i>British Journal of Surgery</i> , <b>2008</b> , 95, 302-9   | 5.3 | 182 |
| 168 | Pathology of the breast. <i>Diagnostic Histopathology</i> , <b>2008</b> , 14, 459-464   | 0.7 |     |
| 167 | Successful management of elderly breast cancer patients treated without radiotherapy. <i>World Journal of Surgical Oncology</i> , <b>2007</b> , 5, 62   | 3.4 | 16  |

|     |   |      |     |
|-----|---|------|-----|
| 166 | P-glycoprotein expression is associated with sestamibi washout in primary hyperparathyroidism. <i>British Journal of Surgery</i> , <b>2007</b> , 94, 1491-5   | 5.3  | 25  |
| 165 | A gene-expression signature to predict survival in breast cancer across independent data sets. <i>Oncogene</i> , <b>2007</b> , 26, 1507-16  | 9.2  | 191 |
| 164 | Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. <i>Oncogene</i> , <b>2007</b> , 26, 1959-70  | 9.2  | 88  |
| 163 | Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. <i>Histopathology</i> , <b>2007</b> , 50, 409-17  | 7.3  | 98  |
| 162 | Non-operative breast pathology: lobular neoplasia. <i>Journal of Clinical Pathology</i> , <b>2007</b> , 60, 1321-7  | 3.9  | 25  |
| 161 | Non-operative breast pathology: columnar cell lesions. <i>Journal of Clinical Pathology</i> , <b>2007</b> , 60, 1307-12   | 3.9  | 41  |
| 160 | MYC amplification in breast cancer: a chromogenic in situ hybridisation study. <i>Journal of Clinical Pathology</i> , <b>2007</b> , 60, 1017-23   | 3.9  | 50  |
| 159 | Application of Finite Difference Time Domain methods to Terahertz Spectroscopy Measurements of Breast Cancer. <i>IEEE MTT-S International Microwave Symposium Digest IEEE MTT-S International Microwave Symposium</i> , <b>2007</b> , |      | 4   |
| 158 | Regulation of p53 tetramerization and nuclear export by ARC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 20826-31   | 11.5 | 89  |
| 157 | Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up. <i>Journal of Medical Screening</i> , <b>2007</b> , 14, 210-4   | 1.4  | 21  |
| 156 | HER2 status in breast cancer--an example of pharmacogenetic testing. <i>Journal of the Royal Society of Medicine</i> , <b>2007</b> , 100, 326-9   | 2.3  | 11  |
| 155 | Lobular in situ neoplasia and columnar cell lesions: diagnosis in breast core biopsies and implications for management. <i>Pathology</i> , <b>2007</b> , 39, 208-16   | 1.6  | 23  |
| 154 | HER2 status in breast cancer--an example of pharmacogenetic testing. <i>Journal of the Royal Society of Medicine</i> , <b>2007</b> , 100, 326-329   | 2.3  | 13  |
| 153 | Reading the prognosis of the individual with breast cancer. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 1545-77.5   |      | 47  |
| 152 | Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 1548-55  | 7.5  | 157 |
| 151 | High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. <i>Genome Biology</i> , <b>2007</b> , 8, R215  | 18.3 | 230 |
| 150 | An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. <i>Genome Biology</i> , <b>2007</b> , 8, R157  | 18.3 | 383 |
| 149 | Upregulation of MICA on high-grade invasive operable breast carcinoma. <i>Cancer Immunity</i> , <b>2007</b> , 7, 17   |      | 38  |

|     |  |      |     |
|-----|--|------|-----|
| 148 | Reproducibility of cancer diagnosis using hair. <i>International Journal of Cancer</i> , <b>2006</b> , 118, 1060; author reply 1061-2  | 7.5  | 3   |
| 147 | Is mammographic spiculation an independent, good prognostic factor in screening-detected invasive breast cancer?. <i>American Journal of Roentgenology</i> , <b>2006</b> , 187, 1377-80                        | 5.4  | 57  |
| 146 | Impact of a national external quality assessment scheme for breast pathology in the UK. <i>Journal of Clinical Pathology</i> , <b>2006</b> , 59, 138-45  | 3.9  | 60  |
| 145 | Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 2468-75  | 12.9 | 163 |
| 144 | The NHS breast screening programme (pathology) EQA: experience in recent years relating to issues involved in individual performance appraisal. <i>Journal of Clinical Pathology</i> , <b>2006</b> , 59, 130-7 | 3.9  | 15  |
| 143 | A consensus prognostic gene expression classifier for ER positive breast cancer. <i>Genome Biology</i> , <b>2006</b> , 7, R101   | 18.3 | 75  |
| 142 | Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. <i>European Journal of Cancer</i> , <b>2006</b> , 42, 357-62  | 7.5  | 112 |
| 141 | Accuracy of mammography in predicting histological extent of ductal carcinoma in situ (DCIS). <i>European Journal of Surgical Oncology</i> , <b>2006</b> , 32, 1089-92   | 3.6  | 10  |
| 140 | Terahertz pulsed imaging and spectroscopy of breast tumors <b>2006</b> , 6386, 178   |      | 2   |
| 139 | Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast. <i>Modern Pathology</i> , <b>2006</b> , 19, 172-9  | 9.8  | 72  |
| 138 | Assessment of Fine Needle Aspiration Cytology and Core Biopsy Samples <b>2006</b> , 17-27  |      |     |
| 137 | Benign Stromal Lesions of the Breast <b>2006</b> , 125-137   |      |     |
| 136 | Fibroepithelial Lesions, Including Fibroadenoma and Phyllodes Tumor <b>2006</b> , 109-124  |      | 1   |
| 135 | Invasive Carcinoma: Other Histologic Prognostic Factors [Size, Vascular Invasion and Prognostic Index <b>2006</b> , 235-240  |      | 1   |
| 134 | Morphology of Ductal Carcinoma in situ <b>2006</b> , 191-200   |      |     |
| 133 | Diagnostic Methodologies: Core Biopsy and Handling of Surgical Specimens <b>2006</b> , 11-16   |      |     |
| 132 | Overview of Immunohistochemistry in Breast Lesions <b>2006</b> , 275-282   |      |     |
| 131 | Invasive Carcinoma: Special Types <b>2006</b> , 201-223  |      | 4   |

|     |  |      |     |
|-----|--|------|-----|
| 130 | The pathological and radiological features of screen-detected breast cancers diagnosed following arbitration of discordant double reading opinions. <i>Clinical Radiology</i> , <b>2005</b> , 60, 1182-7   | 2.9  | 74  |
| 129 | Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. <i>American Journal of Surgical Pathology</i> , <b>2005</b> , 29, 734-46   | 6.7  | 219 |
| 128 | Clinical value of epidermal growth factor receptor expression in primary breast cancer. <i>Advances in Anatomic Pathology</i> , <b>2005</b> , 12, 271-3  | 5.1  | 33  |
| 127 | E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. <i>Histopathology</i> , <b>2005</b> , 46, 685-93  | 7.3  | 132 |
| 126 | Breast pathology practice: most common problems in a consultation service. <i>Histopathology</i> , <b>2005</b> , 47, 445-57  | 7.3  | 37  |
| 125 | Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. <i>Modern Pathology</i> , <b>2005</b> , 18, 26-35  | 9.8  | 196 |
| 124 | Selective use of post-mastectomy flap irradiation in high-risk breast cancer patients. <i>Breast</i> , <b>2005</b> , 14, 298-303   | 3.6  |     |
| 123 | "Inflammatory" breast cancer. <i>Surgical Oncology</i> , <b>2005</b> , 14, 133-43  | 2.5  | 20  |
| 122 | High-resolution analysis of 16q22.1 in breast carcinoma using DNA amplifiable probes (multiplex amplifiable probe hybridization technique) and immunohistochemistry. <i>International Journal of Cancer</i> , <b>2005</b> , 114, 720-9   | 7.5  | 18  |
| 121 | High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. <i>International Journal of Cancer</i> , <b>2005</b> , 116, 340-50 | 7.5  | 443 |
| 120 | Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. <i>International Journal of Cancer</i> , <b>2005</b> , 117, 248-55   | 7.5  | 115 |
| 119 | Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?. <i>Cancer Immunology, Immunotherapy</i> , <b>2005</b> , 54, 149-56  | 7.4  | 28  |
| 118 | Sections of the nipple and quadrants in mastectomy specimens for carcinoma are of limited value. <i>Journal of Clinical Pathology</i> , <b>2005</b> , 58, 543-5  | 3.9  | 21  |
| 117 | The value of immunohistochemistry in sentinel lymph node histopathology in breast cancer. <i>British Journal of Cancer</i> , <b>2005</b> , 92, 2201-5  | 8.7  | 34  |
| 116 | Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. <i>Endocrine-Related Cancer</i> , <b>2005</b> , 12 Suppl 1, S99-S111   | 5.7  | 160 |
| 115 | Histological risk factors, prognostic indicators <b>2005</b> , 254-265   |      |     |
| 114 | Best Practice No 179. Guidelines for breast needle core biopsy handling and reporting in breast screening assessment. <i>Journal of Clinical Pathology</i> , <b>2004</b> , 57, 897-902   | 3.9  | 73  |
| 113 | Loss of CD55 is associated with aggressive breast tumors. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 2797-803   | 12.9 | 39  |

|     |   |     |     |
|-----|---|-----|-----|
| 112 | Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast. <i>British Journal of Cancer</i> , <b>2004</b> , 90, 1538-42                                    | 8.7 | 9   |
| 111 | Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located at 16q22.1. <i>British Journal of Cancer</i> , <b>2004</b> , 91, 1591-6   | 8.7 | 28  |
| 110 | Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. <i>British Journal of Cancer</i> , <b>2004</b> , 91, 1532-42                          | 8.7 | 195 |
| 109 | Identification of carcinoma cells in peripheral blood samples of patients with advanced breast carcinoma using RT-PCR amplification of CK7 and MUC1. <i>Breast</i> , <b>2004</b> , 13, 35-41                          | 3.6 | 20  |
| 108 | Are medullary breast cancers an indication for BRCA1 mutation screening? A mutation analysis of 42 cases of medullary breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2004</b> , 85, 81-8             | 4.4 | 15  |
| 107 | Phenotypic similarities in bilateral breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2004</b> , 85, 255-61  | 4.4 | 21  |
| 106 | Expression of luminal and basal cytokeratins in human breast carcinoma. <i>Journal of Pathology</i> , <b>2004</b> , 203, 661-71   | 9.4 | 442 |
| 105 | Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis. <i>Journal of Pathology</i> , <b>2004</b> , 203, 754-61  | 9.4 | 33  |
| 104 | The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. <i>Journal of Pathology</i> , <b>2004</b> , 204, 93-100 | 9.4 | 124 |
| 103 | Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. <i>Journal of Pathology</i> , <b>2004</b> , 204, 121-30  | 9.4 | 78  |
| 102 | Randomized clinical trial comparing radioisotope occult lesion localization and wire-guided excision for biopsy of occult breast lesions. <i>British Journal of Surgery</i> , <b>2004</b> , 91, 1575-7                | 5.3 | 108 |
| 101 | Metastatic carcinoma of the breast with tubular features: differences compared with metastatic ductal carcinoma of no specific type. <i>Clinical Oncology</i> , <b>2004</b> , 16, 119-24                              | 2.8 | 4   |
| 100 | Brain metastases from breast cancer: identification of a high-risk group. <i>Clinical Oncology</i> , <b>2004</b> , 16, 345-9  | 2.8 | 120 |
| 99  | Best Practice No 176: Updated recommendations for HER2 testing in the UK. <i>Journal of Clinical Pathology</i> , <b>2004</b> , 57, 233-7  | 3.9 | 134 |
| 98  | Ductal carcinoma in situ: diagnosis and classification. <i>Current Diagnostic Pathology</i> , <b>2004</b> , 10, 204-210   |     | 3   |
| 97  | Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma. <i>Clinical Radiology</i> , <b>2004</b> , 59, 895-902   | 2.9 | 40  |
| 96  | Patterns of metastatic breast carcinoma: influence of tumour histological grade. <i>Clinical Radiology</i> , <b>2004</b> , 59, 1094-8   | 2.9 | 30  |
| 95  | Diagnosis of axillary nodal metastases by ultrasound-guided core biopsy in primary operable breast cancer. <i>British Journal of Cancer</i> , <b>2003</b> , 89, 1310-3  | 8.7 | 199 |



|    |  |     |     |
|----|--|-----|-----|
| 94 | Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2003</b> , 27, 11-5                                       | 6.7 | 103 |
| 93 | X-ray refraction effects: application to the imaging of biological tissues. <i>British Journal of Radiology</i> , <b>2003</b> , 76, 301-8  | 3.4 | 97  |
| 92 | Excision biopsy findings of patients with breast needle core biopsies reported as suspicious of malignancy (B4) or lesion of uncertain malignant potential (B3). <i>Histopathology</i> , <b>2003</b> , 42, 331-6                   | 7.3 | 87  |
| 91 | Expert opinion: Reporting needle core biopsies of breast carcinomas. <i>Histopathology</i> , <b>2003</b> , 43, 84-90   | 7.3 | 11  |
| 90 | Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. <i>Journal of Pathology</i> , <b>2003</b> , 199, 418-23                    | 9.4 | 206 |
| 89 | Prognostic significance of BRCA1 expression in sporadic breast carcinomas. <i>Journal of Pathology</i> , <b>2003</b> , 200, 207-13   | 9.4 | 49  |
| 88 | Loss of CD59 expression in breast tumours correlates with poor survival. <i>Journal of Pathology</i> , <b>2003</b> , 200, 633-9  | 9.4 | 64  |
| 87 | Expression of p27kip1 in breast cancer and its prognostic significance. <i>Journal of Pathology</i> , <b>2003</b> , 201, 451-9   | 9.4 | 40  |
| 86 | Prognostic factors for patients with hepatic metastases from breast cancer. <i>British Journal of Cancer</i> , <b>2003</b> , 89, 284-90  | 8.7 | 147 |
| 85 | Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features. <i>British Journal of Cancer</i> , <b>2003</b> , 89, 660-5   | 8.7 | 103 |
| 84 | Is the presence of mammographic comedo calcification really a prognostic factor for small screen-detected invasive breast cancers?. <i>Clinical Radiology</i> , <b>2003</b> , 58, 54-62  | 2.9 | 37  |
| 83 | An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. <i>Human Pathology</i> , <b>2003</b> , 34, 1009-15   | 3.7 | 129 |
| 82 | Size of invasive breast cancer and risk of local recurrence after breast-conservation therapy. <i>European Journal of Cancer</i> , <b>2003</b> , 39, 2462-9  | 7.5 | 39  |
| 81 | Spindle cell carcinoma of the breast: a case series of a rare histological subtype. <i>European Journal of Surgical Oncology</i> , <b>2003</b> , 29, 600-3   | 3.6 | 44  |
| 80 | The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification. <i>Breast Cancer Research</i> , <b>2003</b> , 5, 254-7 | 8.3 | 88  |
| 79 | Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 4306-13   | 2.2 | 118 |
| 78 | HER-2 in breast cancer--methods of detection, clinical significance and future prospects for treatment. <i>Critical Reviews in Oncology/Hematology</i> , <b>2002</b> , 43, 231-44  | 7   | 26  |
| 77 | Neuroendocrine differentiation and prognosis in breast adenocarcinoma. <i>Histopathology</i> , <b>2002</b> , 40, 215-23  | 7.3 | 107 |

|    |  |     |    |
|----|--|-----|----|
| 76 | Diffraction-enhanced imaging: improved contrast and lower dose x-ray imaging <b>2002</b> ,   |     | 11 |
| 75 | Extent of ductal carcinoma in situ within and surrounding invasive primary breast carcinoma. <i>British Journal of Surgery</i> , <b>2001</b> , 88, 1324-9  | 5.3 | 8  |
| 74 | Breast cancer diagnosis using scattered x rays? <b>2001</b> , 4320, 547  |     | 4  |
| 73 | An audit of "equivocal" (C3) and "suspicious" (C4) categories in fine needle aspiration cytology of the breast. <i>Cytopathology</i> , <b>2001</b> , 12, 219-26                                      | 1.3 | 32 |
| 72 | Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2001</b> , 65, 135-44        | 4.4 | 31 |
| 71 | Growth pattern of ductal carcinoma in situ (DCIS): a retrospective analysis based on mammographic findings. <i>British Journal of Cancer</i> , <b>2001</b> , 85, 225-7                               | 8.7 | 32 |
| 70 | Detecting which invasive cancers at mammographic screening saves lives?. <i>Journal of Medical Screening</i> , <b>2001</b> , 8, 86-90  | 1.4 | 12 |
| 69 | Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease?. <i>Journal of Medical Screening</i> , <b>2001</b> , 8, 149-51                          | 1.4 | 55 |
| 68 | E-cadherin as a prognostic indicator in primary breast cancer. <i>British Journal of Cancer</i> , <b>2001</b> , 85, 1958-638.7   |     | 61 |
| 67 | Preoperative assessment of prognostic factors in breast cancer. <i>Journal of Clinical Pathology</i> , <b>2001</b> , 54, 20-4  | 3.9 | 56 |
| 66 | Pathological validation and significance of micrometastasis in sentinel nodes in primary breast cancer. <i>Breast Cancer Research</i> , <b>2001</b> , 3, 113-6                                       | 8.3 | 32 |
| 65 | False-negative breast screening assessment: what lessons can we learn?. <i>Clinical Radiology</i> , <b>2001</b> , 56, 385-8  | 2.9 | 60 |
| 64 | Predicting invasion in mammographically detected microcalcification. <i>Clinical Radiology</i> , <b>2001</b> , 56, 828-32.9  |     | 62 |
| 63 | Prognostic and predictive factors in primary breast cancer and their role in patient management: The Nottingham Breast Team. <i>European Journal of Surgical Oncology</i> , <b>2001</b> , 27, 229-38 | 3.6 | 69 |
| 62 | Sentinel node biopsy for breast cancer may have little to offer four-node-samplers. results of a prospective comparison study. <i>European Journal of Cancer</i> , <b>2001</b> , 37, 1076-80         | 7.5 | 43 |
| 61 | Mammographic size of ductal carcinoma in situ does not predict the presence of an invasive focus. <i>European Journal of Cancer</i> , <b>2001</b> , 37, 459-62                                       | 7.5 | 31 |
| 60 | Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. <i>International Journal of Cancer</i> , <b>2000</b> , 85, 643-8  | 7.5 | 69 |
| 59 | Breast cancer diagnosis using scattered X-rays. <i>Journal of Synchrotron Radiation</i> , <b>2000</b> , 7, 348-52  | 2.4 | 71 |

|    |   |     |     |
|----|---|-----|-----|
| 58 | Metaplastic carcinoma of the breast arising within complex sclerosing lesion: a report of five cases. <i>Histopathology</i> , <b>2000</b> , 36, 203-9   | 7.3 | 73  |
| 57 | c-erbB-4 protein expression in human breast cancer. <i>British Journal of Cancer</i> , <b>2000</b> , 82, 1163-70  | 8.7 | 82  |
| 56 | Loss of heterozygosity in bilateral breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2000</b> , 64, 241-51   | 4.4 | 32  |
| 55 | Pathological assessment of sentinel lymph-node biopsies in patients with breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2000</b> , 436, 97-101   | 5.1 | 8   |
| 54 | Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. <i>Modern Pathology</i> , <b>2000</b> , 13, 730-5  | 9.8 | 102 |
| 53 | When have mammographic calcifications been adequately sampled at needle core biopsy?. <i>Clinical Radiology</i> , <b>2000</b> , 55, 548-53  | 2.9 | 41  |
| 52 | Ultrasound guided core biopsy of suspicious mammographic calcifications using high frequency and power Doppler ultrasound. <i>Clinical Radiology</i> , <b>2000</b> , 55, 390-4  | 2.9 | 33  |
| 51 | Digital imaging improves upright stereotactic core biopsy of mammographic microcalcifications. <i>Clinical Radiology</i> , <b>2000</b> , 55, 374-7  | 2.9 | 19  |
| 50 | Needle core biopsy of the breast. <i>Current Diagnostic Pathology</i> , <b>2000</b> , 6, 200-205  |     | 6   |
| 49 | Pathological prognostic factors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>1999</b> , 31, 209-23   | 7.3 | 119 |
| 48 | Microinvasive carcinoma of the breast: diagnostic criteria and clinical relevance. <i>Histopathology</i> , <b>1999</b> , 35, 470-2  | 7.3 | 7   |
| 47 | Endocrine response and resistance in breast cancer: a role for the transcription factor Fos. <i>International Journal of Cancer</i> , <b>1999</b> , 84, 54-61   | 7.5 | 17  |
| 46 | An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer. <i>Journal of Pathology</i> , <b>1999</b> , 187, 523-9   | 9.4 | 76  |
| 45 | Bilateral breast carcinomas: do they have similar mammographic features?. <i>Clinical Radiology</i> , <b>1999</b> , 54, 434-7   | 2.9 | 4   |
| 44 | Mammographic features of ductal carcinoma in situ (DCIS) present on previous mammography. <i>Clinical Radiology</i> , <b>1999</b> , 54, 644-6   | 2.9 | 48  |
| 43 | Is mammography of value in women with disseminated cancer of unknown origin?. <i>Clinical Oncology</i> , <b>1999</b> , 11, 90-2   | 2.8 | 7   |
| 42 | A critical appraisal of existing classification systems of epithelial hyperplasia and in situ neoplasia of the breast with proposals for future methods of categorization: where are we going?. <i>Seminars in Diagnostic Pathology</i> , <b>1999</b> , 16, 202-8 | 4.3 | 21  |
| 41 | The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. <i>Cancer</i> , <b>1998</b> , 83, 1529-1539   | 6.4 | 64  |

|    |  |      |     |
|----|--|------|-----|
| 40 | Prognostic factors in invasive carcinoma of the breast. <i>Clinical Oncology</i> , <b>1998</b> , 10, 14-7  | 2.8  | 9   |
| 39 | Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: a comparative study with long follow-up. <i>Human Pathology</i> , <b>1998</b> , 29, 915-23 | 3.7  | 69  |
| 38 | The accuracy of breast ultrasound in the evaluation of clinically benign discrete, symptomatic breast lumps. <i>Clinical Radiology</i> , <b>1998</b> , 53, 490-2   | 2.9  | 45  |
| 37 | The detection of ductal carcinoma in situ at mammographic screening enables the diagnosis of small, grade 3 invasive tumours. <i>British Journal of Cancer</i> , <b>1997</b> , 75, 542-4                     | 8.7  | 34  |
| 36 | Radiological features of papillary carcinoma of the breast. <i>Clinical Radiology</i> , <b>1997</b> , 52, 865-8  | 2.9  | 33  |
| 35 | Mammographic and pathological features of breast cancer detected at first incident round screening. <i>Breast</i> , <b>1997</b> , 6, 259-265   | 3.6  | 6   |
| 34 | Correlations between the mammographic features of screen detected invasive breast cancer and pathological prognostic factors. <i>Breast</i> , <b>1997</b> , 6, 146-149                                       | 3.6  | 24  |
| 33 | Intratumoural heterogeneity of proliferation in invasive breast carcinoma evaluated with MIB1 antibody. <i>Breast</i> , <b>1997</b> , 6, 171-176   | 3.6  | 27  |
| 32 | Predictors of response to second-line endocrine therapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>1997</b> , 45, 219-24  | 4.4  | 30  |
| 31 | Routine audit of breast fine needle aspiration (FNA) cytology specimens and aspirator inadequate rates. <i>Cytopathology</i> , <b>1997</b> , 8, 236-47   | 1.3  | 28  |
| 30 | Screening interval breast cancers: mammographic features and prognosis factors. <i>Radiology</i> , <b>1996</b> , 199, 811-7  | 20.5 | 151 |
| 29 | The impact of core-biopsy on pre-operative diagnosis rate of screen detected breast cancers. <i>Clinical Radiology</i> , <b>1996</b> , 51, 562-5   | 2.9  | 54  |
| 28 | Pure mucinous breast cancer-mammographic and ultrasound findings. <i>Clinical Radiology</i> , <b>1996</b> , 51, 421-42.9   | 2.9  | 39  |
| 27 | Is ipsilateral mammography worthwhile in Paget's disease of the breast?. <i>Clinical Radiology</i> , <b>1996</b> , 51, 35-8  | 2.9  | 46  |
| 26 | The positive predictive value of mammographic signs: a review of 425 non-palpable breast lesions. <i>Clinical Radiology</i> , <b>1996</b> , 51, 277-81   | 2.9  | 60  |
| 25 | Prognostic significance of serum c-erbB-2 protein in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>1996</b> , 40, 251-5   | 4.4  | 63  |
| 24 | Diagnosis of breast cancer with core-biopsy and fine needle aspiration cytology. <i>ANZ Journal of Surgery</i> , <b>1996</b> , 66, 592-4   | 1    | 18  |
| 23 | The role of pre-operative diagnosis in breast cancer. <i>Histopathology</i> , <b>1996</b> , 28, 563-6  | 7.3  | 32  |

|    |  |      |     |
|----|--|------|-----|
| 22 | United Kingdom national audit of breast fine needle aspiration cytology in 1990-91--organization and level of activity. <i>Cytopathology</i> , <b>1996</b> , 7, 316-25   | 1.3  | 3   |
| 21 | UK national audit of breast fine needle aspiration cytology in 1990-91: diagnostic criteria. <i>Cytopathology</i> , <b>1996</b> , 7, 326-32  | 1.3  | 1   |
| 20 | C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. <i>British Journal of Cancer</i> , <b>1996</b> , 74, 229-33  | 8.7  | 103 |
| 19 | Proliferative activity in invasive breast carcinoma. <i>Journal of Clinical Pathology</i> , <b>1996</b> , 49, 868-9  | 3.9  |     |
| 18 | Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. <i>Histopathology</i> , <b>1995</b> , 27, 205-18  | 7.3  | 193 |
| 17 | Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. <i>Histopathology</i> , <b>1995</b> , 27, 219-26          | 7.3  | 146 |
| 16 | The assessment of multiple variables on breast carcinoma fine needle aspiration (FNA) cytology specimens: method, preliminary results and prognostic associations. <i>Cytopathology</i> , <b>1995</b> , 6, 316-24                            | 1.3  | 18  |
| 15 | Prognostic factors in primary breast carcinoma. <i>Journal of Clinical Pathology</i> , <b>1995</b> , 48, 981-3   | 3.9  | 25  |
| 14 | Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. <i>British Journal of Cancer</i> , <b>1995</b> , 71, 146-9                                | 8.7  | 145 |
| 13 | Local recurrence after simple mastectomy. <i>British Journal of Surgery</i> , <b>1994</b> , 81, 386-9  | 5.3  | 55  |
| 12 | Ductal carcinoma in situ of the breast: correlation between mammographic and pathologic findings. <i>American Journal of Roentgenology</i> , <b>1994</b> , 162, 1307-11  | 5.4  | 103 |
| 11 | Screening-detected and symptomatic ductal carcinoma in situ: mammographic features with pathologic correlation. <i>Radiology</i> , <b>1994</b> , 191, 237-40   | 20.5 | 39  |
| 10 | The expression of alpha B-crystallin in epithelial tumours: a useful tumour marker?. <i>Journal of Pathology</i> , <b>1994</b> , 174, 209-15   | 9.4  | 41  |
| 9  | Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. <i>Histopathology</i> , <b>1994</b> , 24, 41-7                                | 7.3  | 234 |
| 8  | The radiological appearances of invasive cribriform carcinoma of the breast. Nottingham Breast Team. <i>Clinical Radiology</i> , <b>1994</b> , 49, 693-5   | 2.9  | 29  |
| 7  | Pathological-radiological correlations in benign lesions excised during a breast screening programme. <i>Clinical Radiology</i> , <b>1994</b> , 49, 853-6  | 2.9  | 28  |
| 6  | Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Nottingham Breast Team. <i>Clinical Radiology</i> , <b>1994</b> , 49, 559-62   | 2.9  | 32  |
| 5  | Mycobacterial cervical lymphadenitis in children: can histological assessment help differentiate infections caused by non-tuberculous mycobacteria from <i>Mycobacterium tuberculosis</i> ?. <i>Histopathology</i> , <b>1993</b> , 22, 59-64 | 7.3  | 33  |

|   |   |         |    |
|---|---|---------|----|
| 4 | Precursor lesions of breast carcinoma. <i>Breast</i> , <b>1993</b> , 2, 220-223   | 3.6     | 6  |
| 3 | Mucins in prostatic carcinoma. <i>Histopathology</i> , <b>1990</b> , 16, 43-6   | 7.3     | 28 |
| 2 | Pathology: ductal carcinoma in situ and lesions of uncertain malignant potential  | 127-145 |    |
| 1 | Genomic profiling defines variable clonal relatedness between invasive breast cancer and primary ductal carcinoma in situ |         | 1  |